PathAI logo

PathAI Launches AISight Link to Support integration Solutions for Laboratory Customers and Biopharma Partners

A suite of integration solutions targeted at scaling digital pathology and AI-powered pathology adoption. 

Boston, MA – September 6, 2023 PathAI, a leading provider of precision pathology solutions, today announced that its recently launched image management system, AISight1, is now available with a full suite of integration solutions, called AISight Link, to meet the needs of various customer segments across the digital pathology ecosystem. The first two integration offerings target laboratories and biopharma partners. Laboratories can now not only streamline workflow through bi-directional integration between their laboratory information systems (LIS) and AISight but also integrate homegrown and third-party algorithms through AISight Link. Additionally, biopharma partners can leverage AISight Link to host and distribute their algorithms directly on AISight. The advancements to workflow optimization and open partner ecosystems are part of efforts to accelerate AI powered pathology adoption.

AISight Link offers laboratories bi-directional integration between client’s LIS and AISight, PathAI’s enterprise digital pathology workflow solution, enabling the management and analysis of whole slide images. Pathologists are able to launch AISight directly from their existing worklist and review digital slides as well as algorithm results in a single session to facilitate their review. AISight Link maintains synchronization between cases open in LIS and AISight to reduce the likelihood of data mismanagement and to reduce sample identification errors. The net result is a seamless integration into the existing workflow of laboratories to drive workflow optimization and efficiency, which is imperative for adoption of digital pathology by laboratories.

“AISight Link’s bi-directional integration with AISight represents a major milestone for PathAI, furthering our ability to embed ourselves within existing lab workflows, ” said Andy Beck, M.D., Ph.D., chief executive officer and co-founder of PathAI. Jim Sweeney, president of PathAI Diagnostics, added, “Interoperability is critical to ensure AI workflows operate seamlessly within traditional workflows to accelerate and facilitate the adoption of AI digital pathology tools at scale. We’ve seen this first-hand in the integrations we’ve led at PathAI Diagnostics.”

In addition to hosting PathAI’s growing menu of algorithms across H&E and IHC applications, AISight Link will also enable biopharma partners to distribute their algorithms on AISight across the growing commercial global footprint of AISight. AISight Link’s open algorithm market will allow any user to select algorithms and deploy any algorithm, whether developed by PathAI or a third party. This will enable biopharma and other algorithm developers to distribute AI digital pathology applications at scale without the need to develop or invest in distribution platforms and infrastructures.

“Among our biopharma partners, we’re seeing increased appetite to leverage the rich feature set and expanding commercial footprint for AISight to distribute their models,” said Pete Romanowich, Vice President of PMO & Platform Products. “AISight Link’s open algorithm market signals our willingness to meet this demand to ensure that new precision medicine solutions are fully integrated and optimized for routine pathologist workflows.”

To learn more about this integration, visit or meet with our team at upcoming conferences including ECP, CAP, and PathVisions.

About PathAI 

PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and diagnostic use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of patient samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases.

PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit
  1. AISight is For Research Use Only. Not for use in diagnostic procedures.

Get In Touch

For media inquiries, please contact [email protected].
Path AI seating area overlooking Fenway Park in Boston